Get Clear Answers To Your Concerns
Janini is a non-invasive prenatal test that analyzes cell-free fetal DNA obtained from blood of the mother and screens for Down Syndrome (chr.21), Edwards Syndrome (chr.18), Patau Syndrome (chr.13) and Gender of fetus. Janini only requires a blood sample from the mother thus has no risk in any way on both mother and baby's health.
Janini test can be performed as early as 9 weeks of pregnancy.
Multiplicom - Belgium, has validated and obtained a CE-IVD marking for its innovative diagnostic product (Clarigo). Biolab has partnered with Multiplicom to offer Janini by clarigo to the region where the samples are sequenced at biolab and the final analysis is jointly generated by biolab and Multiplicom.
Incidence of trisomy conditions:
Down Syndrome: 1 in 800 newborns
Edwards Syndrome: 1 in 6,000 newborns
Patau Syndrome: 1 in 16,000 newborns
Janini test limitations:
Janini test can’t be performed for the following categories -
Test results are delivered in just 8 working days after the sample is received.